



Driving Global Innovation & Commercialization Through Partnerships



Monday, November 19, 2007

8:40 am – 10:00 am

Opening Remarks – Capital Hall 1B

Gary Hannah, Chair, OCRI Board of Directors, President & CEO, Vocantas Inc.
The Honourable John Wilkinson, Minister of Research and Innovation

Opening Plenary – Capital Hall 1B

Of Partnerships and Convergent Technologies: The Art of Bringing Ideas, People and Technologies Together

Ogan Gurel, MD, Managing Director, XRoads Solutions Group, LLC (Chicago, IL)

Dr. Gurel is part of the Healthcare Industry vertical and helps lead the group focused on serving life sciences and pharmaceutical clients. Ogan's specific areas of expertise include business strategy development, organizational realignment, clinical transformation, innovation management and marketing strategy. Ogan's previous work experience includes Aesis Group Sg2 and Booz, Allen & Hamilton working with both large and small clients spanning the healthcare services, health insurance, biopharma and medical device sectors. He holds an M.D. degree from the Columbia University College of Physicians & Surgeons, an M.Phil degree in Biochemistry & Molecular Biophysics from Columbia and an A.B. degree in Biochemical Sciences from Harvard University. Dr. Gurel has taught at Harvard, Columbia, Roosevelt and New York Universities; he is published in the peer-reviewed scientific literature and currently holds a faculty position at the University of Illinois – Chicago as Adjunct Associate Professor of Bioengineering. Ogan is a noted thought leader with regular commentaries in a number of venues and a host of the internet TV talk show "Insights in Medicine" on InTimeTV.

10:00 am – 10:30am

Networking & Refreshment Break – Capital Hall Foyer

	<i>Therapeutic Stream</i>	<i>Cleantech Stream</i>	<i>Medical Devices Stream</i>
10:30 am – 12:00 pm	<p><i>Clusters and International Partnerships</i></p> <p><i>Capital Hall 1B</i></p> <p>Industrial collaborations and clusters are a way to ensure that competitive advantages of various stakeholders are fully exploited. Hear</p>	<p><i>What's Driving the Cleantech Market?</i></p> <p><i>Capital Hall 2B</i></p> <p>This session will explore the various segments of the economy that are pulling greener products into the market place, such as green buildings, energy, government</p>	<p><i>The Role of Wireless Technologies in Healthcare</i></p> <p><i>Capital Hall 3B</i></p> <p>Learn about the latest innovations and applications of wireless technologies in healthcare. Hear from leading experts in the</p>

	<p>from leading experts on models and best practices for industrial clusters and international partnerships.</p> <p>Moderator: Dr. Robert Foldes, Executive Director, YORKbiotech Inc.</p> <p>Policies for Cluster Creation: Findings from the ISRN Research Initiative David A. Wolfe, Professor, University of Toronto (Toronto, ON)</p> <p>International Perspective on Canada's Competitiveness Dr. Lawrence C. Mahan, Director & Strategic Advisor, Biosciences, Maryland Department of Business & Economic Development (Baltimore, MD)</p> <p>Challenges and Strategies for Driving Therapeutic Research Through International Partnerships International Consortium on Anti Virals (ICAV) Dr. Jeremy Carver, ICAV CEO, CSO, Trent University, (Peterborough, ON)</p>	<p>procurement, automotive, chemicals and composite sectors. Speakers will review the specific reasons for this demand in their markets and will reveal high potential near-term opportunities as well as cover long-term trends.</p> <p>Moderator: Chris Henderson, President, Lumos Energy, Chairman, The Delphi Group (Ottawa, ON)</p> <p>Kevin Hydes, Chair, World Green Building Council (Toronto, ON)</p> <p>Dr. Peter Frise, CEO, Auto 21, Ontario BioAuto Council (Guelph, ON)</p> <p>Duncan Stewart, Director of Research, Deloitte Canada (Ottawa, ON)</p> <p>Tom Gale, President and CEO Ensyn Technologies - Chemicals from biomass sources (Ottawa, ON)</p>	<p>field of wireless medical devices.</p> <p>Wireless Solutions for Disease Management Marshall S. Stanton, M.D., Vice President, Remote Disease Management, Medtronic, Inc. (Minneapolis, MN)</p> <p>Wireless, Wearable Technology for Long-Term Monitoring of Chronic Patients Dr. Paolo Bonato, Assistant Professor, Department of Physical Medicine and Rehabilitation, Harvard Medical School (Boston, MA)</p> <p>Wireless in Healthcare – Mobility, Security and Standards Bruce Wallace, Leader Healthcare Solutions, Nortel Business Solutions (Ottawa, ON)</p>
<p>12:00 pm – 1:30 pm</p>	<p><i>Keynote Luncheon – Colonel By Salon</i></p> <p><i>Triple Bottom Line Management</i> Jeff Westeinde, President and CEO of Quantum-Murray, V.P. Windmill Developments (Ottawa, ON)</p> <p>Jeff Westeinde is the Chief Executive Officer of Quantum Murray LP, Canada's largest environmental decommissioning contractor. Jeff co-founded the Quantum Environmental Group, a national full service environmental remediation and hazardous waste materials management company, in 1992 and championed a merger with Murray Demolition, Canada's largest demolition contractor in 2007 to form Quantum Murray LP. Quantum Murray employs over 700 professionals from offices throughout British Columbia, Alberta, Saskatchewan and Ontario.</p>		
<p>1:30 pm – 3:00 pm</p>	<p><i>Future of Medicine: Translation to Practice</i></p> <p><i>Capital Hall 1B</i></p> <p>As we learn more about the body and how genetics play a role in treatment we have discovered that one size doesn't fit all. This</p>	<p><i>Technology, Science and Research behind Cleantech</i></p> <p><i>Capital Hall 2B</i></p> <p>There are significant new funding sources aligning to support research in the various components of the Clean Tech sector. This</p>	<p><i>Commercialization Strategies for Medical Devices</i></p> <p><i>Capital Hall 3B</i></p> <p>Getting a medical device to market can often be an arduous and complex exercise. Hear from leading experts in the field of technology</p>

	<p>session will explore how a personalized medicine approach has affected research as well as clinical practice. In addition, it will take things a step further and explore the bigger picture of systems medicine and how regulatory and reimbursement practices may change.</p> <p>Moderator: Ken Newport, Chair, OCRI Life Sciences Advisory Council (Ottawa, ON)</p> <p>Systems Health & Medicine Dr. Howard Federoff, Executive Vice President for Health Sciences, Executive Dean of the School of Medicine, Georgetown University (Washington, DC)</p> <p>A “Systems Medicine” Approach to Pulmonary Hypertension Dr. Duncan J. Stewart, CEO and Scientific Director, OHRI (Ottawa, ON)</p> <p>A Genetic Approach to the Treatment and Prevention of Cardiovascular Disease Dr. Michael Gollob, Cardiac Electrophysiologist, University of Ottawa Heart Institute</p>	<p>session will look at both the sources of new funding as well as have senior research leaders discuss areas of opportunity and challenges in the sector where research can make significant contributions in both shorter as well as longer term time frame.</p> <p>Moderator: Dr. Marc Fortin, ADM Research Agriculture and Agri-Food Canada (Ottawa, ON)</p> <p>Kevin Gellatly, Vice President Alliances, Performance Plants (Kingston, ON)</p> <p>Dr. Dan Wayner, Director General, NRC-Steacie Institute for Molecular Science (NRC-SIMS) (Ottawa, ON)</p> <p>Carole Champion, Director, Business Development, Centre of Excellence for Energy, Ontario Centres of Excellence (Ottawa, ON)</p> <p>Dr. Handan Tezel, Professor, Department of Chemical Engineering, University of Ottawa (Ottawa, ON)</p>	<p>commercialization on working back from a target commercialization date, policy initiatives to expedite commercialization, and deal-making tips.</p> <p>Moderator: Dr. Morris (Mickey) Milner, President & CEO, htx.ca - The Health Technology Exchange</p> <p>Strategies for Engaging Public Relations Services for a Successful Launch Case Study: Touch Bionics Francis Moran, inmedia Public Relations (Ottawa, ON)</p> <p>Regulatory Requirements and Strategy Considerations for Combination Products Diana Salditt, Distinguished Regulatory Affairs Advisor, Medtronic, Inc. (Minneapolis, MN)</p> <p>Patenting Therapeutic/Diagnostic Delivery Devices—Maximizing Marketing Potential Daphne C. Lainson, Associate, Patent Agent & Lawyer, Smart & Biggar (Ottawa, ON)</p>
--	--	--	---

3:00 pm – 3:30 pm Networking & Refreshment Break – Capital Hall Foyer

<p>3:30 pm – 5:00 pm</p>	<p><i>Best Practices for Turning Innovative Ideas into Commercial Products</i></p> <p>Capital Hall 1B</p> <p>Revolutionary ideas are born everyday. Many of them never see the light of day. This session will bring to light the best practices needed to turn innovation into commercial products.</p> <p>Moderator: Michelle Scarborough, Director, Investment & Commercialization, OCRI (Ottawa, ON)</p>	<p><i>Evolution of Cleantech Training to Meet Human Resource Needs</i></p> <p>Capital Hall 2B</p> <p>This session highlights the new educational / training offerings from colleges and universities needed to supply skilled resources to meet the needs of the rapidly emerging Cleantech sector.</p> <p>Moderator: Jeff Tolan, Senior Staff Scientist, Iogen Corporation (Ottawa, ON)</p> <p>Dr. Maike Luiken, Dean, Applied Research, Business Development and Innovation Sustainable Development (Sarnia, ON)</p>	<p><i>Drug and Device Convergence: A Conflict of Cultures</i></p> <p>Capital Hall 3B</p> <p>The convergence of drugs, devices and diagnostics is leading to innovative health solutions and new opportunities for business growth and product differentiation. Hear from leading experts on best practices and strategies for integrating technologies and differing corporate cultures.</p> <p>Moderator: Dr. Peter Morand, President, Peter Morand & Associates (Ottawa, ON)</p> <p>Framing the Value of Convergent</p>
---------------------------------	--	--	--

	<p>Role of a VC in Helping Commercialize Early Stage Innovation Richard Meadows, Managing Partner, CTI Life Sciences Fund (Montreal, QC)</p> <p>Turning Ideas into Commercial Success Mr. René Gosselin, Managing Partner, Groupe CREA (Montreal, QC)</p> <p>Duncan Stewart, Director of Research, Deloitte Canada (Ottawa, ON)</p>	<p>Don Young, Dean of Applied Sciences, St. Lawrence College (Kingston, ON)</p> <p>Michael Goss, Director, Kemptville College of the University of Guelph (Kemptville, ON)</p> <p>Brent Wootton, Senior Scientist, Centre for Alternative Wastewater Treatment (Lindsay, ON)</p>	<p>Technologies for Investors T. "Teo" Forcht Dagi, General Partner, HLM Venture Partners (Boston, MA)</p> <p>How Drug-Device Combination Products are Altering Medical Practice from Development to Regulation to Treatment Dr. Annemarie Moseley, Acting CEO Aggregate Therapeutics (Palo Alto, CA)</p> <p>Blood, Sweat & IPO Dr. Ian Smith, Director General, NRC Institute for Bidiagnostics (NRC-IBD) (Winnipeg, MB)</p>
5:00 pm – 7:00 pm	Opening Reception		

Tuesday, November 20, 2007

7:30 am – 3:00 pm Registration Open

8:30 am – 10:00 am	<p>Therapeutic Stream</p> <p>CNS Therapeutics and Blood-Brain Barrier <i>Capital Hall 1B</i></p> <p>While the Blood Brain Barrier maintains a protective shell keeping toxins from entering the brain, it also limits the delivery options for certain drugs, rendering them ineffective. Explore current research and therapeutic options to overcome the challenge of the Blood Brain Barrier.</p> <p>Moderator: Ken Lawless, President & CEO, Epitope Capital Corp. (Ottawa, ON)</p> <p>Blood-Brain Barrier in CNS Drug Development Danica Stanimirovic, Group Leader, Cerebrovascular Research Group, NRC Institute for Biological Sciences (Ottawa, ON)</p> <p>Development of a New Peptide Vector, AngioPep, for the Delivery of Therapeutic Drugs to the Brain Dr. Reinhard Gabathuler, CSO, AngioChem Inc. (Montreal, QC)</p>	<p>Medical Devices Stream</p> <p>Challenges in Executing Multi-Institutional IP Agreements <i>Capital Hall 3B</i></p> <p>The nature of research and science is becoming increasingly collaborative. Conducting research is becoming more expensive and collaboration is necessary to be competitive; multi-disciplinary teams work together to leverage individual strengths fostering increased innovation and creating stronger end products. Collaboration comes with significant challenges: negotiating complex legislative and legal frameworks, inconsistent policy frameworks, differences in organizational cultures, and a lack of accountability structures to ensure IP deployment. This panel will explore the barriers and enablers to multi-institutional agreements by looking at the current state of innovation in Canada, and lessons learned from elsewhere.</p> <p>Moderator: Joanne Johnson, Director of the Performance, Evaluation, Economics and Research group in Advisory Services, PricewaterhouseCoopers LLP.</p>
--------------------	---	--

	<p>Dynamic Study of the Blood-Brain Barrier Permeabilisation Process using MRI Dr. David Fortin, Associate Professor, National Bank of Canada Research, Chair for the Treatment of Brain Cancer, Director, Division of Neurosurgery, Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke (Sherbrooke, QC)</p>	<p>Barriers to Innovation in Canada: Executing Multi-Institutional IP Agreements Dr. John Culley, Director, Office of Intellectual Property and Commercialization, Agriculture and Agri-Food Canada (Ottawa, ON)</p> <p>Key Elements of Legislation in the U.S. Requiring Exploitation of IP, Motivating Factors for the Creation of the Legislation, Key Challenges and Potential Lessons for Canada Joe Allen, Vice President and General Manager, Wheeling Operations, WVHTC Foundation (Wheeling, WV)</p> <p>Challenges and Lessons Learned: Exploiting IP Developed from Public Institutions Dr. Louis Lamontagne, President & CEO, PainCeptor Pharma Corporation (Montreal, QC)</p>
--	--	---

10:00 am – 10:30 am Networking & Refreshment Break – Capital Hall Foyer

	<p>Therapeutic Stream</p>	<p>Cleantech Stream</p>	<p>Medical Devices Stream</p>
<p>10:30 am – 12:00 pm</p>	<p>Novel Drug Development Capital Hall 1B</p> <p>This session will take an in-depth look at non-traditional approaches to drug discovery. Past practices have proven to be lengthy and expensive and have had the added challenge of mutating viruses. Innovation and new approaches have allowed researchers to better understand how disease and infection are controlled at the molecular and physiological levels and to target specific entities based on this knowledge. Join us as we explore the advances in drug discovery.</p> <p>Moderator: Mark Adam, CEO and Founder, AgaPharm Corp. (Ottawa, ON)</p> <p>Algorithmic Technologies in Future Drug Discovery: Opportunities and Risks Dr. Marcel Thürk, Managing Director and Chief Technologist, Matrix Advanced Solutions Germany GmbH (Goettingen, Germany)</p> <p>Anti-Cancer Antibody Drugs</p>	<p>Investing in Cleantech: Market Trends and Opportunities Capital Hall 2B</p> <p>This session will feature investors who are investing in the Cleantech sector, who will speak about emerging appetite for these types of investments and their experience to date and exciting things that they see upon the horizon.</p> <p>Moderator: Dr. Kevin Goheen, Director, SRED Services, McLarty & Co. (Richmond, ON)</p> <p>Rick Whittaker, V.P., Sustainable Development Technology Canada (Ottawa, ON)</p> <p>Ian Tharp, Senior Analyst – Alternative Energy & Power, Dundee Securities (Toronto, ON)</p> <p>Claude Haw, Managing Partner, Venture Coaches (Canadian Cleantech Fund) (Ottawa, ON)</p>	<p>How to Pick a Partner? Capital Hall 3B</p> <p>Partnerships allow firms to focus on their competitive advantage, ideally creating a superior end product. However, choosing the right partner is critical. What makes a good partner? What should one look for when choosing partner? What can partners do to ensure a fruitful relationship? This panel featuring a number of expert presenters will answer these questions and more.</p> <p>Moderator: Jeffrey Dale, President & CEO, OCRI (Ottawa, ON)</p> <p>Why the Rising Canadian Dollar Makes Partnering a Necessity Martin Hauschild, President & CEO, Seprotech (Ottawa, ON)</p> <p>Leveraging Trade Missions to Capitalize on International Opportunities Larry Petovello, Director of Economic Development, City of Mississauga (Mississauga, ON)</p>

	<p>Dan Pereira, Vice President of Research, Arius Research Inc. (Toronto, ON)</p> <p>Breaking New Ground with Food Safety Vaccine Technology Graeme McRae, President & CEO, Bioniche Life Sciences (Belleville, ON)</p>		<p>Innovative Strategies to Integrate Development, Manufacturing & Commercialization of Customized Medical Devices Steve Carkner, President & CEO, Panacis (Ottawa, ON)</p>
<p>12:00 pm – 1:30 pm</p>	<p>Lunch – Colonel By Salon</p>		
<p>1:30 pm – 3:00 pm</p>	<p>Novel Cancer Detection and Therapeutics <i>Capital Hall 1B</i></p> <p>This session will take an in-depth look at non-traditional approaches to drug discovery. Past practices have proven to be lengthy and expensive and have had the added challenge of mutating viruses. Innovation and new approaches have allowed researchers to better understand how disease and infection are controlled at the molecular and physiological levels and to target specific entities based on this knowledge. Join us as we explore the advances in drug discovery.</p> <p>Moderator: Peter Brenders, President & CEO, BIOTECanada</p> <p>Mitochondrial DNA: A 'Biosensor' for Prostate Cancer Detection Ryan Parr, Vice President, Research & Development, Genesis Genomics Inc. (Thunder Bay, ON)</p> <p>Discovery, Identification, and Verification of Cancer Biomarkers: A Convergence of Mass Spectrometry-Based Proteomics and Immunohistochemistry Dr. Michael Siu, Distinguished Research Professor, NSERC / MDS Analytical Technologies Chair, Department of Chemistry, Director, Centre for Research in Mass Spectrometry (Toronto, ON)</p>	<p>Organizational Infrastructure: Best Practices for Economic Development <i>Capital Hall 2B</i></p> <p>This session features the sharing of best practices by economic development professionals who are focusing on elements of the Cleantech sector as the engine of their local economic development. Speakers will share their experiences gained in engaging the various assets in their community, strengthening these assets and bringing them together to support the growth of Cleantech companies. This will be a very hands-on and interactive session with active participation between the audience and speakers.</p> <p>Moderator: Brian Barkley, General Manager, Eastern Ontario Model Forest (Ottawa, ON)</p> <p>Matt McLean, Executive Director, Southwestern Ontario BioProducts Innovation Network (SOBIN) (Chatham, ON)</p> <p>John DiPaolo, Senior Manager, Eastern Lake Ontario Regional Innovation Network (elorin) (Kingston, ON)</p> <p>Andy Brown, Chief Administrative Officer, Municipality of North Grenville (North Grenville, ON)</p> <p>Ron Kehrig, Vice President, AgWest Bio</p>	<p>Medical Device and Diagnostic Development: The Bridge from Bench to Bedside <i>Capital Hall 3B</i></p> <p>An in depth analysis of the device development process and how it differs from pharmaceutical development. This session will present a comprehensive cataloguing of the major pathways for devices and diagnostics and their continued evolution post-market.</p> <p>Diagnosis and Treatment in Place Greg Arnsdorff, President Abbott Point of Care (New Jersey)</p> <p>How to Develop a Collaborative Clinical Relationship Dr. Rejean Munger, Visual Optics Laboratory, Clifford, Gladys and Lorna J. Wood Chair for Vision Research, University of Ottawa Eye Institute, Ottawa Health Research Institute (Ottawa, ON)</p> <p>The Convergence of Medical Devices with Therapeutics: Emerging Opportunities Wendy Naimark, Principle Research Scientist, Boston Scientific (Boston, MA)</p>

	<p>Cancer Vaccines: Moving Towards Reality Thorsten Vogel, Principal Scientist, Immunotherapeutics Section Head, (Immuno- Microbiology Platform, Research), Sanofi Pasteur (Toronto, ON)</p>	(Saskatoon, SK)	
--	---	-----------------	--

3:00 pm – 3:30 pm Networking & Refreshment Break – Capital Hall Foyer

<p>3:30 pm – 5:00 pm</p>	<p>Closing Plenary - <i>Capital Hall 1B</i></p> <p><i>Winning Worldwide by Doing Less and Deciding Later: Leveraging Partnerships and Parallelism for Innovation and Commercialization</i> Michael Davies, Chairman, Endeavour Partners and CTO, EquuSys Inc (Boston, MA)</p> <p>Innovation and successful commercialization are always challenging, but doubly so for companies that are (a) innovating in complex and risky domains such as medical devices, therapeutics or cleantech and (b) targeting global opportunities. Moreover the challenges are becoming tougher as these domains converge with each other, and with information and communications technologies (ICT).</p> <p>This session will summarize the key challenges in driving global innovation and commercialization, sketch future scenarios and, most importantly, outline effective strategies that use partnerships to provide a springboard for success. It will challenge some conventional wisdom, explaining how doing less and deciding later can create better products that generate higher revenues, with development that takes less time, requires fewer resources and has lower risk.</p>
---------------------------------	--

5:00 pm Conference Close